Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin

David Healy*, Audrey Bahrick, Maarten Bak, Angelo Barbato, Rocco Salvatore Calabrò, Barbara M Chubak, Fiammetta Cosci, Antonei B Csoka, Barbara D'Avanzo, Silvia Diviccaro, Silvia Giatti, Irwin Goldstein, Heiko Graf, Wayne J G Hellstrom, Michael S Irwig, Emmanuele A Jannini, Paddy K C Janssen, Mohit Khera, Manoj Therayil Kumar, Joanna Le NouryMichał Lew-Starowicz, David E J Linden, Celine Lüning, Dee Mangin, Roberto Cosimo Melcangi, Omar Walid Muquebil Ali Al Shaban Rodríguez, Jalesh N Panicker, Arianna Patacchini, Amy M Pearlman, Caroline F Pukall, Sanjana Raj, Yacov Reisman, Rachel S Rubin, Rudy Schreiber, Stuart Shipko, Barbora Vašečková, Ahad Waraich

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)65-76
Number of pages12
JournalInternational Journal of Risk and Safety in Medicine
Volume33
Issue number1
Early online date26 Oct 2021
DOIs
Publication statusPublished - 22 Feb 2022

Keywords

  • Post-SSRI sexual dysfunction
  • antidepressants
  • selective serotonin reuptake inhibitors
  • finasteride
  • isotretinoin
  • GENITAL AROUSAL DISORDER
  • PREMATURE EJACULATION
  • DOUBLE-BLIND
  • PERSISTENT
  • CITALOPRAM
  • EFFICACY
  • SAFETY

Cite this